Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era

Prognosis for patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Immune-based therapeutic treatments such as CD19 Chimeric Antigen Receptor (CAR) T cell therapies have dramatically changed the treatment landscape for R/R DLBCL leading to durable remissions in ~ 50...

Full description

Bibliographic Details
Main Authors: Suheil Albert Atallah-Yunes, Michael J. Robertson, Utpal P. Davé, Paola Ghione, Fabiana Perna
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
diffuse large B-cell lymphoma
immunotherapy
chimeric antigen receptor T-cell therapy
target
discovery
high-risk
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.901365/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.901365/full

Similar Items